Skip to main content

False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications.

Publication ,  Journal Article
Cheran, SK; Nielsen, ND; Patz, EF
Published in: AJR Am J Roentgenol
May 2004

OBJECTIVE: The aim of this study was to determine the stage and outcome of patients with primary lung tumors who had a negative finding on a FDG positron emission tomography (PET) study at the time of diagnosis. MATERIALS AND METHODS: A total of 3912 patients between November 1994 and August 2002 underwent thoracic or whole-body PET performed at our institution for evaluation of a pulmonary abnormality suspicious for lung cancer. We identified 20 patients with a biopsy-proven primary lung tumor and a negative PET study at the time of presentation. Surgical, pathologic, radiographic imaging, and clinical follow-up information were reviewed to confirm the histology, stage, and outcome. RESULTS: Tumor histology included adenocarcinoma (n = 7, 35%), bronchioalveolar cell carcinoma (n = 6, 30%), carcinoid (n = 3, 15%), squamous cell carcinoma (n = 2, 10%), otherwise unspecified non-small cell lung cancer (n = 1, 5%), and sarcomatoid neoplasm (n = 1, 5%). One patient with bronchioalveolar cell carcinoma had multifocal stage IV disease, and all other patients were stage IA (n = 14, 70%) or stage IB (n = 5, 25%). Eighteen (90%) of the 20 patients underwent curative surgical resection. No patient is known to have tumor recurrence after resection, and three (17%) of the 18 patients are known to be living and free of disease 5 years after surgery. CONCLUSION: With the exception of bronchioalveolar cell carcinoma and carcinoid, newly diagnosed lung cancers with negative PET findings are usually early-stage diseases and are associated with a favorable prognosis, suggesting that indeterminate pulmonary nodules, which are PET-negative, can be managed conservatively with serial radiographic studies to monitor for signs of growth. These findings warrant further study and should be confirmed with sufficient follow-up in a large cohort of patients with PET-negative lung lesions.

Duke Scholars

Published In

AJR Am J Roentgenol

DOI

ISSN

0361-803X

Publication Date

May 2004

Volume

182

Issue

5

Start / End Page

1129 / 1132

Location

United States

Related Subject Headings

  • Tomography, Emission-Computed
  • Retrospective Studies
  • Radiopharmaceuticals
  • Prognosis
  • Nuclear Medicine & Medical Imaging
  • Neoplasm Staging
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cheran, S. K., Nielsen, N. D., & Patz, E. F. (2004). False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications. AJR Am J Roentgenol, 182(5), 1129–1132. https://doi.org/10.2214/ajr.182.5.1821129
Cheran, Sendhil Kumar, Nathan D. Nielsen, and Edward F. Patz. “False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications.AJR Am J Roentgenol 182, no. 5 (May 2004): 1129–32. https://doi.org/10.2214/ajr.182.5.1821129.
Cheran, Sendhil Kumar, et al. “False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications.AJR Am J Roentgenol, vol. 182, no. 5, May 2004, pp. 1129–32. Pubmed, doi:10.2214/ajr.182.5.1821129.
Cheran SK, Nielsen ND, Patz EF. False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications. AJR Am J Roentgenol. 2004 May;182(5):1129–1132.

Published In

AJR Am J Roentgenol

DOI

ISSN

0361-803X

Publication Date

May 2004

Volume

182

Issue

5

Start / End Page

1129 / 1132

Location

United States

Related Subject Headings

  • Tomography, Emission-Computed
  • Retrospective Studies
  • Radiopharmaceuticals
  • Prognosis
  • Nuclear Medicine & Medical Imaging
  • Neoplasm Staging
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Humans